Clinical Trial Update: Trastuzumab Plus Docetaxel and Capecitabine For First Line Treatment of Her2-Positive Advanced Gastric Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update of first-line trastuzumab plus docetaxel and capecitabine in HER2-positive advanced gastric cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Taxotere (docetaxel)
• Xeloda (capecitabine)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Stomach Neoplasms, Neoplasms Metastasis | Phase 2 | Status: COMPLETED